Alkermes (ALKS) Stock News

Alkermes (ALKS) will present new research on ALKS 2680, its novel oral orexin 2 receptor agonist, at SLEEP 2025 conference. The company will showcase eight posters and two oral presentations, including key findings from Phase 1 studies. ALKS 2680 is in phase 2 development for narcolepsy type 1, type 2, and idiopathic hypersomnia. Notable results include: - Statistically significant wake-associated qEEG profile vs placebo - Well-tolerated single doses with significant improvements in mean sleep latency - No cardiac safety concerns in healthy volunteers - Phase 1b study showed positive results across all tested doses The company is currently conducting Phase 2 Vibrance Studies and expects to share topline results from Vibrance-1 in early Q3. The presentations will also include research on the clinical, economic, and humanistic burden of narcolepsy, along with findings from patient interviews on idiopathic hypersomnia.

Alkermes (ALKS) reported Q1 2025 financial results with total revenues of $306.5 million and GAAP net income of $22.5 million ($0.13 per share). Key product revenues included VIVITROL at $101.0M, ARISTADA at $73.5M, and LYBALVI at $70.0M. LYBALVI showed strong growth with 23% revenue increase year-over-year. The company maintains a solid cash position of $916.2 million. Notably, Alkermes achieved a milestone in its ALKS 2680 program, completing enrollment in the Vibrance-1 phase 2 study for narcolepsy type 1, with topline results expected in early Q3. The company reiterated its 2025 financial guidance and continues to focus on strategic objectives in neuroscience, particularly the development of its orexin 2 receptor agonist program.

A new Harris Poll survey commissioned by Alkermes reveals insights into Alcohol Use Disorder (AUD) diagnosis and treatment among 300 adults aged 21-64. The survey highlights that:

47% of respondents were diagnosed following hospital/ER visits, while only 28% were identified through routine screenings. About 79% reported negative feelings upon diagnosis, including fear and shame. Among those treated, 70% are currently in treatment, utilizing various methods including prescription medication (50%), behavioral therapy (46%), and support groups (43%).

The survey found that healthcare providers play a crucial role, with 80% of respondents discussing prescription medications with their providers. Treatment shows positive impacts, with over 50% reporting improvements in physical health (61%), quality of life (60%), and relationships. Notably, 96% of current patients report satisfaction with their treatment.

Despite approximately 28 million U.S. adults having AUD, only about 2 million received treatment in the past year, highlighting a significant treatment gap.

Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company focused on neuroscience, has announced it will host a conference call and webcast presentation on Thursday, May 1, 2025, at 8:00 a.m. ET to discuss its first quarter financial results.

The presentation will be accessible through the Investors section of Alkermes' website, with dial-in options available for U.S. callers (+1 877 407 2988) and international callers (+1 201 389 0923). A replay will be available approximately two hours after the event.

Alkermes specializes in developing treatments for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, with ongoing research in neurological disorders including narcolepsy and idiopathic hypersomnia. The company maintains operations across Ireland, Massachusetts, and Ohio.

Alkermes plc (Nasdaq: ALKS) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's management will join a webcast panel discussion titled 'Development of Orexin Receptor Agonist in Sleep-Wake Disorders' at 11:45 a.m. EDT.

The global biopharmaceutical company, focused on neuroscience innovations, maintains a portfolio of commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders, specifically narcolepsy and idiopathic hypersomnia.

The company operates from its headquarters in Ireland, with additional facilities including a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. The panel discussion webcast will be accessible through the Investors section of Alkermes' website and remain archived for 14 days.

Alkermes (ALKS) has launched Vibrance-3, a Phase 2 clinical study evaluating ALKS 2680 for idiopathic hypersomnia (IH). The study will assess the safety and efficacy of their novel oral selective orexin 2 receptor agonist versus placebo in adults with IH.

The randomized, double-blind trial will enroll approximately 96 patients across U.S., Australia, and Europe sites. Participants will receive one of three doses (10mg, 14mg, or 18mg) or placebo once-daily for eight weeks. The primary endpoint measures decrease in sleepiness using the Epworth Sleepiness Scale score.

This development follows encouraging Phase 1b data and addresses a significant unmet need, as over 90% of patients in a recent Sleep Consortium survey reported moderate to high impact of IH symptoms on their lives. IH affects an estimated 40,000 people in America.

A new national survey conducted by The Harris Poll for Alkermes (ALKS) reveals critical insights into healthcare providers' perspectives on treating schizophrenia and bipolar I disorder (BDI). The September 2024 survey, involving over 250 healthcare providers, highlights that 98% of respondents consider patient quality of life equally important as symptom management.

Key findings show that medication adherence is a primary concern, with patients switching medications frequently - BDI patients average seven switches and schizophrenia patients eight switches in their lifetime. About 66% of providers reported good/excellent quality of life for BDI patients, compared to only 21% for schizophrenia patients.

The survey revealed that providers prioritize symptom management (98% for BDI, 97% for schizophrenia) and quality of life improvements (96% for BDI, 94% for schizophrenia) when considering treatment efficacy. Common treatment challenges include medication effectiveness (82%) and side effects (81%). Most providers (97%) seek options to minimize the number of different treatments patients need to take.

Alkermes plc (Nasdaq: ALKS) has announced its participation in two major upcoming investor conferences in March 2025. The company will engage in webcast fireside chats at the TD Cowen 45th Annual Health Care Conference on March 5 at 9:50 a.m. ET and the Leerink Partners Global Healthcare Conference 2025 on March 12 at 11:20 a.m. ET.

The webcasts will be accessible through the Investors tab on Alkermes' website and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with a portfolio including treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations across Ireland, Massachusetts, and Ohio.

Alkermes (ALKS) reported strong financial results for Q4 and full-year 2024, with total revenues of $1.56 billion. The company achieved 18% year-over-year growth in proprietary product net sales, reaching over $1 billion. Key highlights include:

- GAAP Net Income from continuing operations of $372.1 million ($2.20 per share)
- Total proprietary net sales reached $1.08 billion
- Year-end cash position of $824.8 million
- Company became debt-free after retiring $290 million in debt

For 2025, Alkermes provided financial guidance including:
- Total revenue expectations of $1.34-1.43 billion
- GAAP Net Income of $175-205 million
- EBITDA guidance of $215-245 million

The company is advancing its neuroscience pipeline, with ALKS 2680 Phase 2 studies in narcolepsy ongoing and data expected in H2 2025.